



## Clinical trial results:

**Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age**

### Summary

EudraCT number	2008-007846-69
Trial protocol	DE ES
Global end of trial date	21 November 2012

### Results information

Result version number	v2 (current)
This version publication date	05 August 2016
First version publication date	23 April 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set Data (typos) were corrected.</li></ul>

### Trial information

#### Trial identification

Sponsor protocol code	112830
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00891176
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 June 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 November 2012
Global end of trial reached?	Yes
Global end of trial date	21 November 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

At approximately 3, 4 and 6 years of age, in subjects who previously received a full vaccination course with Hib-MenC conjugate vaccine co-administrated with DTPa-containing and pneumococcal conjugate vaccines or with MenC conjugate vaccines co-administered with DTPa/Hib containing and GSK Biologicals' 10Pn-PD-DiT conjugate vaccines, and who participated in the blood sampling subset of study 10PN-PD-DIT-017:

- To evaluate the antibody persistence with respect to the MenC component of the Hib-MenC conjugate vaccine in terms of percentage of subjects with rSBA-MenC titres  $\geq 1:8$

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 May 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	72 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 108
Country: Number of subjects enrolled	Spain: 186
Country: Number of subjects enrolled	Poland: 306
Worldwide total number of subjects	600
EEA total number of subjects	600

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	600
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

All subjects who received the full vaccination course corresponding to their group in the primary vaccination study 107005 and in the booster vaccination study 109507 and who were part of the blood sampling subset were asked to participate in this long-term follow up study comprising 3 time points. No vaccine was given.

### Pre-assignment period milestones

Number of subjects started	600
Number of subjects completed	581

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	No vaccination received: 19
----------------------------	-----------------------------

### Period 1

Period 1 title	Long term Persistence (Visit 1)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
Arm title	Synflorix-Meningitec 1 Group

Arm description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Experimental
Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age.

No vaccine was administered during this long-term follow up study.

Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:  
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Investigational medicinal product name	Infanrix Penta
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:  
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

Investigational medicinal product name	Infanrix IPV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:  
Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain) No vaccine was administered during this long-term follow up study

<b>Arm title</b>	Synflorix-NeisVac-C 1 Group
------------------	-----------------------------

Arm description:

Subjects who received concomitantly in the primary study (107005):  
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.  
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).  
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Active comparator
Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:  
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age.  
No vaccine was administered during this long-term follow up study

Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:  
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

Investigational medicinal product name	Prevenar
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Synflorix-Menitorix 1 Group
------------------	-----------------------------

**Arm description:**

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

Investigational medicinal product name	Meningitec
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

<b>Arm title</b>	Prevenar-Menitorix 1 Group
------------------	----------------------------

**Arm description:**

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

---

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Number of subjects in period 1<sup>[1]</sup></b>	Synflorix-Meningitec 1 Group	Synflorix-NeisVac-C 1 Group	Synflorix-Menitorix 1 Group
Started	144	147	149
Completed	144	147	149

<b>Number of subjects in period 1<sup>[1]</sup></b>	Prevenar-Menitorix 1 Group
Started	141
Completed	141

---

**Notes:**

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Some subjects were enrolled but did not start the trial.

---

**Period 2**

Period 2 title	Long term Persistence (Visit 2)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

---

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Synflorix-Meningitec 2 Group

---

**Arm description:**

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Experimental
Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Synflorix-NeisVac-C 2 Group
------------------	-----------------------------

**Arm description:**

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Active comparator
Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Synflorix-Menitorix 2 Group
------------------	-----------------------------

**Arm description:**

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Prevenar-Menitorix 2 Group
------------------	----------------------------

**Arm description:**

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
----------	--------------



Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Synflorix-Meningitec 2 Group	Synflorix-NeisVac-C 2 Group	Synflorix-Menitorix 2 Group
Started	140	142	142
Completed	140	142	142

<b>Number of subjects in period 2<sup>[2]</sup></b>	Prevenar-Menitorix 2 Group
Started	137
Completed	137

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Some subjects did not come back for the subsequent visits.

### Period 3

Period 3 title	Long term Persistence (Visit 3)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Synflorix-Meningitec 3 Group

Arm description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Synflorix-NeisVac-C 3 Group
------------------	-----------------------------

Arm description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Arm type	Active comparator
Investigational medicinal product name	Menitorix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Synflorix-Menitorix 3 Group
------------------	-----------------------------

Arm description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Arm title</b>	Prevenar-Menitorix 3 Group
------------------	----------------------------

Arm description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Pneumococcal conjugate vaccine GSK1024850A
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

<b>Number of subjects in period 3<sup>[3]</sup></b>	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 3 Group
Started	131	138	135
Completed	131	138	135

<b>Number of subjects in period 3<sup>[3]</sup></b>	Prevenar-Menitorix 3 Group
Started	135
Completed	135

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Some subjects did not come back for the subsequent visits.

## Baseline characteristics

### Reporting groups

Reporting group title	Synflorix-Meningitec 1 Group
-----------------------	------------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-NeisVac-C 1 Group
-----------------------	-----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-Menitorix 1 Group
-----------------------	-----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Prevenar-Menitorix 1 Group
-----------------------	----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group values	Synflorix-Meningitec 1 Group	Synflorix-NeisVac-C 1 Group	Synflorix-Menitorix 1 Group
Number of subjects	144	147	149
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			

Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: months arithmetic mean standard deviation	37.1 ± 1.17	37.2 ± 1.2	37.3 ± 1.18
Gender categorical Units: Subjects			
Female	71	65	86
Male	73	82	63

<b>Reporting group values</b>	Prevenar-Menitorix 1 Group	Total	
Number of subjects	141	581	
Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous Units: months arithmetic mean standard deviation	37.3 ± 1.28	-	
Gender categorical Units: Subjects			
Female	71	293	
Male	70	288	

## End points

### End points reporting groups

Reporting group title	Synflorix-Meningitec 1 Group
-----------------------	------------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-NeisVac-C 1 Group
-----------------------	-----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-Menitorix 1 Group
-----------------------	-----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Prevenar-Menitorix 1 Group
-----------------------	----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Synflorix-Meningitec 2 Group
-----------------------	------------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-NeisVac-C 2 Group
-----------------------	-----------------------------

#### Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-Menitorix 2 Group
-----------------------	-----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Prevenar-Menitorix 2 Group
-----------------------	----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Synflorix-Meningitec 3 Group
-----------------------	------------------------------

Reporting group description:

Subjects who received concomitantly in the primary study 107005:

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

(In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-NeisVac-C 3 Group
-----------------------	-----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

(In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-Menitorix 3 Group
-----------------------	-----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

Reporting group title	Prevenar-Menitorix 3 Group
-----------------------	----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (107005):

3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.

3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

**Primary: Number of subjects with Meningococcal serogroup C serum bactericidal titers using rabbit complement (rSBA-MenC) equal to or above the cut-off value 1:8**

End point title	Number of subjects with Meningococcal serogroup C serum bactericidal titers using rabbit complement (rSBA-MenC) equal to or above the cut-off value 1:8 <sup>[1]</sup>
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

At 3, 4 and 6 years of age

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	139	134	128	146
Units: Subjects				
rSBA-MenC	120	97	31	144

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	137	137	143	128
Units: Subjects				
rSBA-MenC	132	55	127	108

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	137	128	134
Units: Subjects				
rSBA-MenC	50	113	98	34

## Statistical analyses



**Secondary: Number of subjects with anti-polyribosyl -ribitol phosphate (Anti-PRP) and antibody concentration equal to or above cut-off**

End point title	Number of subjects with anti-polyribosyl -ribitol phosphate (Anti-PRP) and antibody concentration equal to or above cut-off
-----------------	-----------------------------------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3, 4 and 6 years of age. The cut-off were 0.15 ug/mL and 1.0 ug/mL

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	132	134	127	139
Units: Subjects				
≥ 0.15 µg/mL	132	133	126	139
≥ 1.0 µg/mL	101	88	85	105

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	136	134	137	130
Units: Subjects				
≥ 0.15 µg/mL	134	132	137	130
≥ 1.0 µg/mL	85	77	127	117

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	138	133	132
Units: Subjects				
≥ 0.15 µg/mL	130	138	132	132
≥ 1.0 µg/mL	110	115	106	100

**Statistical analyses**

No statistical analyses for this end point

## Secondary: Number of subjects with pneumococcal serotypes concentration equal to and above the cut-off values

End point title	Number of subjects with pneumococcal serotypes concentration equal to and above the cut-off values
End point description:	
End point type	Secondary
End point timeframe:	
At 3, 4 and 6 years of age	

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	141	136	128	146
Units: Subjects				
Anti-1	138	130	121	143
Anti-4	138	130	108	141
Anti-5	140	136	125	144
Anti-6B	137	131	125	143
Anti-7F	141	135	125	146
Anti-9V	138	135	125	144
Anti14	141	136	128	146
Anti-18 C	141	136	127	146
Anti-19F	141	135	128	146
Anti-23	140	133	127	145

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	144	133
Units: Subjects				
Anti-1	135	129	135	124
Anti-4	133	123	140	127
Anti-5	137	131	142	131
Anti-6B	134	133	139	125
Anti-7F	138	134	141	130
Anti-9V	135	133	141	128
Anti14	138	137	144	132
Anti-18 C	138	136	140	130
Anti-19F	136	137	144	133
Anti-23	137	136	140	126

End point values	Synflorix-	Prevenar-	Prevenar-	Prevenar-
------------------	------------	-----------	-----------	-----------

	Menitorix 3 Group	Menitorix 1 Group	Menitorix 2 Group	Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	140	136	133
Units: Subjects				
Anti-1	114	83	100	101
Anti-4	106	133	132	126
Anti-5	124	101	115	112
Anti-6B	128	137	132	130
Anti-7F	129	68	85	113
Anti-9V	126	139	135	131
Anti14	130	140	136	133
Anti-18 C	125	139	136	128
Anti-19F	130	137	136	133
Anti-23	128	139	134	133

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with opsonophagocytic activity

End point title	Number of subjects with opsonophagocytic activity
End point description:	
End point type	Secondary
End point timeframe:	
At 3 years of age	

End point values	Synflorix-Meningitec 1 Group	Synflorix-NeisVac-C 1 Group	Synflorix-Menitorix 1 Group	Prevenar-Menitorix 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	131	131	132
Units: Subjects				
Opsono-1 [N=131;131;131;131]	30	32	29	14
Opsono-4 [N=126;127;129;128]	54	48	43	77
Opsono-5 [N=130;130;129;132]	73	47	55	5
Opsono-6B [N=128;127;124;131]	84	81	78	115
Opsono-7F [N=131;130;131;130]	128	130	131	126
Opsono-9V [N=131;131;129;132]	127	131	127	124
Opsono-14 [N=129;128;128;131]	110	118	106	112
Opsono-18C [N=126;121;123;122]	51	68	44	48
Opsono-19F [N=130;130;131;132]	105	108	89	91
Opsono-23F [N=125;124;125;132]	106	112	113	129

## Statistical analyses

No statistical analyses for this end point

### Secondary: Antibody concentrations against vaccine pneumococcal serotypes

End point title	Antibody concentrations against vaccine pneumococcal serotypes
-----------------	----------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3, 4 and 6 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	141	136	128	146
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1	0.26 (0.22 to 0.3)	0.22 (0.19 to 0.27)	0.19 (0.16 to 0.23)	0.23 (0.19 to 0.26)
Anti-4	0.27 (0.23 to 0.32)	0.22 (0.19 to 0.26)	0.14 (0.11 to 0.17)	0.23 (0.2 to 0.27)
Anti-5	0.46 (0.39 to 0.54)	0.47 (0.37 to 0.59)	0.37 (0.3 to 0.45)	0.39 (0.33 to 0.46)
Anti-6B	0.59 (0.45 to 0.76)	0.74 (0.53 to 1.01)	1.71 (1.32 to 2.23)	0.56 (0.45 to 0.71)
Anti-7F	0.58 (0.5 to 0.67)	0.51 (0.41 to 0.63)	0.61 (0.49 to 0.78)	0.51 (0.43 to 0.59)
Anti-9V	0.6 (0.49 to 0.73)	0.52 (0.42 to 0.65)	0.76 (0.56 to 1.01)	0.54 (0.44 to 0.66)
Anti-14	1.33 (1.04 to 1.7)	1.51 (1.18 to 1.92)	2.84 (2.17 to 3.73)	1.09 (0.88 to 1.35)
Anti-18C	0.6 (0.5 to 0.71)	0.49 (0.41 to 0.59)	0.52 (0.41 to 0.66)	0.84 (0.73 to 0.97)
Anti-19F	2.06 (1.58 to 2.69)	2.66 (1.92 to 3.67)	3.91 (3.01 to 5.1)	1.63 (1.27 to 2.09)
Anti-23F	0.73 (0.58 to 0.92)	0.98 (0.71 to 1.35)	1.71 (1.26 to 2.3)	0.69 (0.55 to 0.88)

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	144	133
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1	0.21 (0.17 to 0.26)	0.22 (0.17 to 0.27)	0.21 (0.18 to 0.25)	0.18 (0.15 to 0.21)

Anti-4	0.21 (0.18 to 0.25)	0.14 (0.11 to 0.17)	0.23 (0.2 to 0.27)	0.2 (0.17 to 0.24)
Anti-5	0.36 (0.3 to 0.42)	0.31 (0.26 to 0.37)	0.41 (0.35 to 0.5)	0.34 (0.28 to 0.42)
Anti-6B	0.65 (0.49 to 0.86)	1.13 (0.87 to 1.48)	0.63 (0.47 to 0.84)	0.78 (0.57 to 1.06)
Anti-7F	0.44 (0.37 to 0.52)	0.59 (0.46 to 0.74)	0.54 (0.45 to 0.66)	0.46 (0.37 to 0.58)
Anti-9V	0.61 (0.46 to 0.81)	0.67 (0.51 to 0.88)	0.47 (0.39 to 0.57)	0.54 (0.4 to 0.72)
Anti-14	1.57 (1.25 to 1.97)	2.22 (1.72 to 2.86)	1 (0.8 to 1.25)	1.41 (1.1 to 1.82)
Anti-18C	0.81 (0.67 to 0.98)	0.75 (0.6 to 0.94)	0.59 (0.48 to 0.71)	0.6 (0.48 to 0.75)
Anti-19F	2.36 (1.7 to 3.29)	3.94 (2.99 to 5.2)	1.35 (1.05 to 1.72)	2.5 (1.8 to 3.48)
Anti-23F	0.84 (0.65 to 1.1)	1.7 (1.27 to 2.26)	0.62 (0.46 to 0.82)	0.98 (0.69 to 1.39)

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	140	136	134
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-1	0.2 (0.15 to 0.26)	0.07 (0.06 to 0.09)	0.08 (0.07 to 0.1)	0.11 (0.09 to 0.13)
Anti-4	0.12 (0.1 to 0.15)	0.35 (0.29 to 0.42)	0.32 (0.27 to 0.39)	0.24 (0.19 to 0.29)
Anti-5	0.3 (0.25 to 0.37)	0.09 (0.07 to 0.1)	0.1 (0.08 to 0.11)	0.13 (0.11 to 0.15)
Anti-6B	1.28 (1 to 1.64)	0.95 (0.77 to 1.18)	0.99 (0.76 to 1.29)	1.73 (1.38 to 2.16)
Anti-7F	0.64 (0.5 to 0.82)	0.07 (0.05 to 0.09)	0.09 (0.07 to 0.12)	0.24 (0.18 to 0.32)
Anti-9V	0.57 (0.42 to 0.79)	0.7 (0.57 to 0.85)	0.72 (0.57 to 0.91)	0.65 (0.51 to 0.83)
Anti-14	2.81 (2.07 to 3.81)	1.48 (1.23 to 1.78)	1.71 (1.38 to 2.12)	2.59 (2.08 to 3.23)
Anti-18C	0.56 (0.43 to 0.74)	0.59 (0.5 to 0.7)	0.49 (0.4 to 0.59)	0.49 (0.39 to 0.62)
Anti-19F	4.24 (3.3 to 5.45)	1.48 (1.07 to 2.05)	2.41 (1.78 to 3.25)	3.11 (2.48 to 3.91)
Anti-23F	1.41 (1.06 to 1.87)	1.36 (1.07 to 1.73)	1.56 (1.16 to 2.09)	2.99 (2.32 to 3.86)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-protein D (anti-PD) antibody concentrations equal or above cut off values

End point title	Number of subjects with anti-protein D (anti-PD) antibody concentrations equal or above cut off values
End point description:	
End point type	Secondary
End point timeframe:	
At 3, 4 and 6 years of age	

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	140	136	128	145
Units: Subjects				
Anti-PD	132	127	113	137

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	144	129
Units: Subjects				
Anti-PD	128	119	136	115

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	139	132	133
Units: Subjects				
Anti-PD	113	69	75	74

### Statistical analyses

No statistical analyses for this end point

### Secondary: Concentration of antibodies against protein D

End point title	Concentration of antibodies against protein D
End point description:	
End point type	Secondary
End point timeframe:	
At 3, 4 and 6 years of age	

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	140	136	128	145
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD	494.6 (414 to 591)	401.1 (338.3 to 475.6)	284.7 (239.5 to 338.4)	444.8 (373.2 to 530.1)

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	138	137	144	129
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD	387.2 (326.7 to 458.9)	278 (236.3 to 327.1)	439.8 (366.4 to 527.9)	334.8 (277.7 to 403.7)

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	139	132	133
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-PD	266.1 (222.2 to 318.8)	100.3 (87.6 to 114.9)	107.9 (94.6 to 123.1)	105.2 (92.4 to 119.8)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values

End point title	Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values
-----------------	------------------------------------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-NeisVac-C 1 Group	Synflorix-Menitorix 1 Group	Prevenar-Menitorix 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107	102	105	102
Units: Subjects				
≥ 10 mIU/mL	105	96	102	99
≥ 100 mIU/mL	77	81	74	74

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations
-----------------	---------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-NeisVac-C 1 Group	Synflorix-Menitorix 1 Group	Prevenar-Menitorix 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	107	102	105	102
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs antibody concentrations	367.5 (256.8 to 525.9)	325.7 (228.3 to 464.7)	288.1 (198.7 to 417.9)	371.4 (254.1 to 542.8)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with Meningococcal serogroup C serum bactericidal titers using rabbit complement (rSBA-MenC) equal to or above cut-off value 1:128

End point title	Number of subjects with Meningococcal serogroup C serum bactericidal titers using rabbit complement (rSBA-MenC) equal
-----------------	-----------------------------------------------------------------------------------------------------------------------



to or above cut-off value 1:128

End point description:

End point type Secondary

End point timeframe:

At 3, 4 and 6 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	139	134	128	146
Units: Subjects				
rSBA-MenC	69	49	11	109

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	137	137	143	128
Units: Subjects				
rSBA-MenC	79	19	98	75

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	137	128	134
Units: Subjects				
rSBA-MenC	15	68	58	14

### Statistical analyses

No statistical analyses for this end point

### Secondary: Meningococcal serogroup C serum bactericidal (rSBA-MenC) titers

End point title Meningococcal serogroup C serum bactericidal (rSBA-MenC) titers

End point description:

End point type Secondary

End point timeframe:

At 3, 4 and 6 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	139	134	128	146
Units: Titer				
geometric mean (confidence interval 95%)				
rSBA-MenC titers	100.5 (75.6 to 133.8)	45.3 (33.2 to 61.8)	7.2 (5.8 to 8.9)	235.3 (189.1 to 292.7)

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	137	137	143	128
Units: Titer				
geometric mean (confidence interval 95%)				
rSBA-MenC titers	146.8 (116.2 to 185.4)	11.9 (8.9 to 16)	167.5 (126 to 222.7)	112.4 (81.8 to 154.6)

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	137	128	134
Units: Titer				
geometric mean (confidence interval 95%)				
rSBA-MenC titers	10.1 (7.9 to 12.9)	84 (61.6 to 114.6)	68.1 (48.4 to 95.9)	8.5 (6.6 to 11.1)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-polyribosyl -ribitol phosphate (anti-PRP) concentrations

End point title	Anti-polyribosyl -ribitol phosphate (anti-PRP) concentrations
-----------------	---------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3, 4 and 6 years of age

End point values	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	132	134	127	139
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-PRP concentrations	2.293 (1.87 to 2.812)	1.767 (1.454 to 2.146)	1.655 (1.339 to 2.045)	2.222 (1.794 to 2.752)

End point values	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	136	134	137	130
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-PRP concentrations	1.738 (1.386 to 2.178)	1.647 (1.298 to 2.09)	4.177 (3.427 to 5.092)	3.804 (3.092 to 4.679)

End point values	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	130	138	133	132
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-PRP concentrations	2.947 (2.396 to 3.624)	3.636 (2.957 to 4.471)	2.805 (2.297 to 3.425)	2.558 (2.065 to 3.168)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with Serious Adverse Events (SAEs)

End point title	Number of subjects with Serious Adverse Events (SAEs)
-----------------	-------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 3, 4 and 6 years of age

<b>End point values</b>	Synflorix-Meningitec 1 Group	Synflorix-Meningitec 2 Group	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 1 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	144	140	131	147
Units: Subjects				
SAE(s)	0	0	0	0
Related SAE(s)	0	0	0	0

<b>End point values</b>	Synflorix-NeisVac-C 2 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 1 Group	Synflorix-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	142	138	149	142
Units: Subjects				
SAE(s)	0	0	0	0
Related SAE(s)	0	0	0	0

<b>End point values</b>	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 1 Group	Prevenar-Menitorix 2 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	135	141	137	135
Units: Subjects				
SAE(s)	0	0	0	0
Related SAE(s)	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations
-----------------	---------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 4 years of age

End point values	Synflorix-Meningitec 2 Group	Synflorix-NeisVac-C 2 Group	Synflorix-Menitorix 2 Group	Prevenar-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	95	102	98	98
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs antibody concentrations	273.5 (183.2 to 408.3)	238.8 (165.6 to 344.3)	174.6 (114.5 to 266.4)	284.7 (190.7 to 425.1)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values

End point title	Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values
-----------------	------------------------------------------------------------------------------------------------------------------------------

End point description:

Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

At 4 years of age

End point values	Synflorix-Meningitec 2 Group	Synflorix-NeisVac-C 2 Group	Synflorix-Menitorix 2 Group	Prevenar-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	95	102	98	98
Units: Subjects				
≥ 10 mIU/mL	86	93	86	90
≥ 100 mIU/mL	67	72	62	72

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with opsonophagocytic activity

End point title	Number of subjects with opsonophagocytic activity
-----------------	---------------------------------------------------

End point description:

Opsonophagocytic activity was measured by a killing-assay. The results were presented as the dilution

of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer of 8.

End point type	Secondary
End point timeframe:	
At 4 years of age	

End point values	Synflorix-Meningitec 2 Group	Synflorix-NeisVac-C 2 Group	Synflorix-Menitorix 2 Group	Prevenar-Menitorix 2 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	131	134	123	128
Units: Subjects				
Opsono-1 (n=131;134;123;128)	33	32	20	12
Opsono-4 (N=127;132;118;126)	49	50	36	72
Opsono-5 (N=129;132;122;128)	65	46	40	5
Opsono-6B (N=128;129;122;126)	93	97	101	111
Opsono-7F (N=131;134;123;128)	131	134	123	126
Opsono-9V (N=130;132;120;126)	125	130	118	122
Opsono-14 (N=126;128;114;121)	96	105	95	110
Opsono-18C (N=113;118;113;118)	34	56	46	45
Opsono-19F (N=131;133;123;128)	87	88	80	89
Opsono-23F (N=129;133;119;121)	98	108	86	111

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations
End point description:	
End point type	Secondary
End point timeframe:	
At 6 years of age	

End point values	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	122	129	125	128
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs antibody concentrations	66.7 (47.2 to 94.1)	64.7 (46.4 to 90.2)	45.7 (32.2 to 64.8)	85.4 (60.4 to 120.6)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-hepatitis B surface antigen (anti- HBs) antibody concentrations equal to or above cut-off values

End point title	Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values
-----------------	------------------------------------------------------------------------------------------------------------------------------

End point description:

Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 years of age

End point values	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	122	129	125	128
Units: Subjects				
≥ 10 mIU/mL	100	103	91	108
≥ 100 mIU/mL	57	62	45	66

## Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations as measured by ChemiLuminescence ImmunoAssay (CLIA)

End point title	Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations as measured by ChemiLuminescence ImmunoAssay (CLIA)
-----------------	-------------------------------------------------------------------------------------------------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 years of age

End point values	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	122	129	125	128
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HBs antibody concentrations	66.7 (47.2 to 94.1)	64.7 (46.4 to 90.2)	45.7 (32.2 to 64.8)	85.4 (60.4 to 120.6)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody as measured by CLIA concentrations equal to or above cut-off values

End point title	Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody as measured by CLIA concentrations equal to or above cut-off values
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Cut-off values assessed were defined as equal to or above 6.2 milli-international units per milliliter (mIU/mL) or equal to or above 10 mIU/mL or equal to or above 100 mIU/mL.

End point type	Secondary
----------------	-----------

End point timeframe:

At 6 years of age

End point values	Synflorix-Meningitec 3 Group	Synflorix-NeisVac-C 3 Group	Synflorix-Menitorix 3 Group	Prevenar-Menitorix 3 Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	122	129	125	128
Units: Subjects				
≥ 6.2 mIU/mL	102	108	98	112
≥ 10 mIU/mL	100	103	91	108
≥ 100 mIU/mL	57	62	45	66

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

From last study contact of the booster study at 17-24 months of age (NCT00463437) until 6 years of age

Adverse event reporting additional description:

Since no vaccine was administered during the study, other adverse events were not assessed.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

### Reporting groups

Reporting group title	Synflorix-Meningitec Group
-----------------------	----------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-NeisVac-C Group
-----------------------	---------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

Reporting group title	Synflorix-Menitorix Group
-----------------------	---------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.

Reporting group title	Prevenar-Menitorix Group
-----------------------	--------------------------

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.

Serious adverse events	Synflorix-Meningitec Group	Synflorix-NeisVac-C Group	Synflorix-Menitorix Group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 144 (0.00%)	0 / 147 (0.00%)	0 / 149 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

<b>Serious adverse events</b>	Prevenar-Menitorix Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 141 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Synflorix-Meningitec Group	Synflorix-NeisVac-C Group	Synflorix-Menitorix Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 144 (0.00%)	0 / 147 (0.00%)	0 / 149 (0.00%)

<b>Non-serious adverse events</b>	Prevenar-Menitorix Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 141 (0.00%)		

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events were recorded in this study.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported